Opinion|Videos|February 9, 2026
Barriers to Managing Alzheimer Disease
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs help overcome social and systemic barriers to Alzheimer care.
Advertisement
Episodes in this series
Panelists discuss how social, financial, and systemic challenges hinder Alzheimer management. Limited access to specialists, diagnostic costs, and caregiver burnout are recurring themes.
Panelists discuss how APPs advocate for patients by navigating insurance processes, connecting families with resources, and promoting equitable access to care regardless of socioeconomic status.
Panelists discuss how addressing these barriers requires policy awareness and community outreach. APPs’ holistic approach positions them as champions of accessible, patient-centered care.
Advertisement
Related to this article
Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5